Maryland Innovation Initiative Logo
JOHNS HOPKINS UNIVERSITY
  • Developing a molecular profiling formalin fixed patient tumor tissue: novel ligation in situ hybridization sequencing (LISH-seq) platform (Larman)
  • Developing a high efficiency sensor for diagnosis of real time electrolyte imbalance Cystic Fibrosis Monitoring (Searson)
  • Developing vapor sensing technologies based on stabilized organic transistors (Katz)
  • Developing SuperPACS: AI Enhanced Tools for Clinical Stratification of Patients at Risk for Cardiac Disease (Ambale Venkatesh)
  • Development of T417, a first-in-class inhibitor of the proto-oncognene PBX1 for the treatment of ovarian cancer and other human malignancies (Wang)
  • Developing a tool for early prediction of patients with sepsis who will develop septic shock: ShockAlert (Winslow)
  • Developing patient derived organoid models (PDO) predicting response to therapy in liver cancer (Selaru)
  • Developing a novel technology for determining the personalized optimal ablation targets in patients with atrial fibrillation (AF) and fibrosis (Trayanova)
  • Developing a potent rBCG as a therapeutic intervention for nonmuscle invasive bladder cancer (Bishai)
  • Developing an inhibitor of neutral sphinghomyelinase2 for the treatment of Alzheimer’s disease (Rojas)
  • Developing a novel therapy initially for triple negative breast cancer (TNBC) with potential for use against many other cancers (Semenza)
  • Optimization of an improved formulation of Mebendazole for treatment of brain and other cancers (Riggins)
  • Developing software for rehabilitation healthcare analytics & prediction (ReHAP) (Gourab)
  • Developing a multicomponent inhibition of hypoxia inducible factor to treat ocular neovascularization (Green)
  • Developing a minimally invasive theranostic device for brain neurooncology (Manbachi)
  • Developing a novel biomarker and ELISA assay for determination of cognitive status in Alzheimer’s disease (Worley)
  • Developing a therapeutic to prevent kidney toxicity in prostate cancer patients receiving PSMA-targeted radiotherapy (Slusher)
  • Developing a device to more accurately target spine during lumbar punctures (LP) to collect cerebrospinal fluid(CSF) (Moghekar)
  • Developing a method to use non-contrast-enhanced MRI and Perfusion index Mapping (Qin)
  • Developing a drug, Ethoxyquin-6, for prevention of chemotherapy-induced peripheral neuropathy (Hoke)
  • Develop a polyionic papillomavirus-like particles (VLP) for the treatment of prostate cancer (Viscidi)
  • Development of Hypoxia Inducible Factor-1 with Polymeric Chitosan Nanoparticles to improve wound healing (Harmon)
  • Developing the Corrie Health Digital Platform: Reinventing cardiac recovery (Martin)
  • Developing Intra-ART: A novel platform for MRI-guided intra-arterial placement of therapeutic agents to treat brain tumors (Pearl)
  • Developing a novel device for effective minimally invasive treatment for urethral strictures (Wright)
  • Developing a cohesive robot-ultrasound probe for prostate biopsy (Stoianovici)
  • Development of immunoswitch for treatment of metastatic melanoma: a novel immunomodulator approach (Schneck)
  • Developing a halofuginone as a disease-modifying therapy for osteoarthritis (Cao)
  • Developing a VLM-modified s-Ontak: a second-generation, Treg-depleting immunotherapy (Bishai)
  • Developing a cardiac RF ablation lesion assessment system (Karmarkar)
  • Developing a first non-invasive ELISA assay for pulmonary arterial hypertension (Everett)
  • SMART surgical tools: optical coherence sensor guided microsurgical tools with enhanced surgical fun (Kang)
  • “Smart” programmable digital stethoscope (Elhilali)
  • Developing a novel blood/sputum diagnostic test for lung cancer (Brock)
  • Developing a novel thyroid cancer specific biomarker panel (Umbricht)
  • Developing a precision medicine approach for treating a subtype of severe pain called allodynia (mechanical pain)(Bosmans)
  • Developing a new class of therapeutic compounds for the treatment of diarrhea predominant irritable bowel syndrome (IBS-D) (Barrow)
  • Developing an injectable nanofiber-hydrogel composite for soft tissue reconstruction (Sacks)
  • Developing a long-acting therapy for Parkinson’s Disease (Ko)
  • Developing an Epigenetic based test for the prediction of postpartum depression in pregnant women (Kaminsky)
  • Developing a 5-HT1A-Receptor: Biomarker stratification of patients with suicidal risk during treatment of pediatric depression (Kaplin)
  • Developing the Renalert System, a monitor for real time renal perfusion which enables clinicians to prevent acute kidney injury (AKI) (Hogue)
  • Repurposing of Cethromycin (QB101) for Malaria Prophylaxis (Sullivan)
  • Developing a new, first-in-class therapeutic to treat a heritable form of retinal degeneration called Leber’s congenital amaurosis (LCA) (Bunz)
  • Developing a new treatment for the autoimmune rheumatic disease, systemic sclerosis(SSc) (Lee)
  • Developing a small molecule PSMA inhibitor to treat Inflammatory Bowel Disease (Hartman-Ph.2)
  • Developing an imaging (FBnTP) agent as a biomarker for tumor aggressiveness and response to chemotherapy in early detection (Madar)
  • Develop color-coded quantitative brain cancer mapping for real-time, cost-effective surgical guidance. (Li)
  • Develop a therapeutic vaccine as a novel treatment for neuromyelitis optica (NMO) (Levy)
  • Develop a potent drug with a novel mechanism for the treatment of leukemia and lymphoma (Slusher)
  • Develop a novel tool for seizure localization in medically refractory epilepsy (Sarma)
  • Developing bifunctional immunostimulatory antibodies for treatment of cancer (Bedi)
  • Develop REMS: Robotic ENT Microsurgery System (Taylor)
  • Develop codeDNA: Advanced Malware Variant Detection (Breiner)
  • Developing biodegradable aAPC particles for cancer immunotherapy (Green)
  • Developing a drug to reverse atherosclerotic heart disease in diabetic mice (Chatterjee)
  • Develop an adaptive robotic platform for expandable, easy to program collaborative industrial robots (Hager)
  • Developing a saliva based rapid diagnostic test for detection of asymptomatic carriers of the malaria parasite (Dinglasan)
  • Improve delivery, enhance efficacy, and prolong glutaminase inhibitor drug levels in the tumor with the ultimate goal of improving outcomes for pancreatic cancer patients (Le)
  • Developing LiFi enabled 3D Optical Imaging for collision safety and autonomous transportation (Torruellas)
  • Improving computer-assisted craniomaxillofacial surgery (Gordon)
  • Using cell permeable peptides derived from Pirt2 mutant protein to treat chronic pain (Dong)
  • Developing a device that will reduce reoperation rates in breast conserving surgery. (Benkoski)
  • Developing a blood test based on methylated gene markers for breast cancer. (Sukumar)
  • Developing an inexpensive tool, called FastStitch, to improve the surgical suture process. (Nguyen)
  • Creating a device to assess cardiac filling pressure for preventing re-hospitalization for heart failure. (Silber)
  • Introduced a diagnostic method for rapid detection of significant coronary heart disease. (McVeigh)
  • Developing a cancer targeting agent, which has special relevance in castration-resistance prostate cancer (In collaboration with University of Maryland, Baltimore County). (Laiho)
  • Developing a device, called MouthLab, to enable the fast sampling of medical data. (Fridman)
  • Developing a new lotion to augments wound healing, improves healing skin quality and reduces scar size. (Walston)
  • Developing a polymeric fore sensor that is used with middle ear titanium prostheses to provide feedback to the surgeon. (Francis)
  • Developing non-invasive quantitative CT imaging-based alternative that will provide accurate and rapid determination of the functional significance of coronary artery disease. (Lardo)
  • Evaluating the efficacy and toxicity of artemisinin dimers in a mouse model and to select the lead   dimer for further development towards clinical studies in humans. (Boger)
  • Develop a prototypic nanoparticle based system to mediate redirected lysis by human antigen-specific cytotoxic T lymphocytes, CTL, to tumor cells that would otherwise not be recognized. (Schneck)
  • Developing a technology to use autologous volar fibroblasts to create new thick skin at the stump site for amputees. (Kang)
  • Commercialize novel chemical exchange saturation transfer (CEST) magnetic resonance imaging  (MRI) biosensors. (van Zijl)
  • Developing a peptide-based therapy for acute and chronic diahrreal diseases. (Zachos)
  • Developing a more effective treatment for seizures using amino acid therapy. (Hartman)
  • Developing a low cost, high speed, wide dynamic range, software configurable, multimodel imaging sensor. (Rizk)
     
MORGAN STATE UNIVERSITY
  • Developing SUMZ: A stormwater utility management system (Hunter)
  • Developing LightTrax: a building occupant lighting tracking system (Nyarko)
  • Developing technology that offers a cost-effective and environmental friendly alternate to produce biofuel using naturally available sea water and the sun’s energy. (Early Charm Ventures-Ph.2)
  • Developing the iCrystal System and new crystallization platforms for rapid drug treatment. (Aslan-Ph.2
     
UNIVERSITY OF MARYLAND BALTIMORE
  • Reinventing transplant transportation: teal-time organ management using the HOMAL and COM App (Scalea)
  • Developing a novel high-efficacy approach to cancer immunotherapy with minimal toxicity (Davila)
  • Developing Elabela into a therapeutic for heart failure (Gong)
  • Developing a transseptal puncture device for left atrial access (Gammie)
  • Developing a diagnostic for non-small cell lung cancer (Jiang)
  • Developing next-generation multi-specific antibody therapeutic (Li)
  • Developing a novel bifunctional antibody for lung cancer therapy (Ren)
  • Developing a novel transRectal Focal Abdominal Cooling (rFAC) device for the treatment of IRI and SIRS (Hu)
  • Developing a blood test for the early detection of lung cancers based on newly-discovered sprRNAs (Mei)
  • Using Synthetic Inhibitory Mucin Protecting Lung Epithelia (SIMPLE) technology to treat pseudomonas lung infections (Lillehoj)
  • Developing a first-in-class therapy for sepsis (Vasta)
  • Developing a portable deficit-adjusted ankle robot for neurologically disabled populations (Macko)
  • Optimization and Validation of a Novel Immunotherapy against Clostridum difficile Infection (CDI). (Feng)
  • Developing a novel system for recombinant protein expression. (In collaboration with University of Maryland, College Park) (Robb)
  • Refining and validating the first universal cancer immunotherapy, At-CAR (Anti-tag Chimeric Antigen Receptor). (Davila-Ph.2)
  • Developing a new target and approach to antibiotic therapy (Wilks)
  • Using magnetic nanoparticles for the treatment of dental disease (Masri)
  • Developing VNLG-152 as a novel targeted therapy for triple negative breast cancer (Njar)
  • Developing a technology for Alzheimer’s disease therapy that targets an inflammatory pathway in asymptomatic and symptomatic patients. (Zimmer)
  • Develop a method to rapidly assess the function of NKT cells in cancer patients (Webb)
  • Developing anti-thrombosis antibody product to improve clinic treatments (Xu)
  • Developing a novel hybrid mesh for the treatment of pelvic organ prolapse. (ZSX Medical-Ph.2)
  • Developing a technology, called RelaxDetect, which can detect biopharmaceutical aggregation via water relaxation in sealed vials. (Bruce Yu)
  • Develop a thermal endoscope for laparoscopy. This technique will reduce serious intraoperative complications by over 50%. (Pearl)
  • Commercialization of an Inflammatory Bowel Disease (IBD) diagnostic based on a microbiome signature technology. (ITVMD-Ph.2)
  • Developing an interactive web-based software that will be commercialized for detecting and addressing parental psychosocial risk factors for child abuse/neglect within healthcare settings. (Dubowitz)
  • Develop a unique opioid analgesic with reduced tolerance. (Coop)
  • Developing a topical cream for treatment of cervical intraepithelial neoplasia. (Khanna)
     
UNIVERSITY OF MARYLAND BALTIMORE COUNTY
  • Apogee scanner, a laser-based spectrographic system for stand-off detection of trace materials (Arnold)
  • Development of bidirectional cannula for arterial access for extracorporeal life support (Griffith)
  • Developing DL5016 as an enhancer for cyclophosphamide-based chemotherapeutics (Wang)
  • Development of NCGC-43 as a novel fast-acting antidepressant (Thompson)
  • Developing a way to detect antibiotic-resistant bacteria in blood (Kostov)
  • Developing a novel drag reduction approach for box trailers TrimJET (Farquhar)
  • Developing an impact-driven piezoelectric energy harvester: ActiveCharge (Lee)
  • LifePower: a self charging power source for implantable devices (Slaughter)
  • SolarSafe: a long-lead-time forecaster of solar storms (Savani)
  • Developing ‘substrate-cage: devices for novel enzyme discovery (Gardner)
  • Developing small molecule pyrimidines potent anticancer therapeutics (Seley-Radtke)
  • Developing a commercialization plan for CRAFT cybersecurity system (ITVMD-Ph.2)
  • Develop an immunotherapy drug (BiTE) for the treatment of cancer. (Ostrand-Rosenberg)
  • Developing an App for real-time audience enhancement and music education during music presentation and concerts. (Dusman-Ph.2)
  • Biomarker discovery and validation for Kinase Inhibitors (Bieberich)
  • Developing a geared infinitely variable transmission with minimal speed fluctuation. (Zhu)
  • Working to increase food safety and agricultural productivity through innovative feed additives. (MycoInnovation)
  • Developing soluble CD80 (CD80-Fc) as a therapeutic agent for the treatment of cancer. (Ostrand-Rosenberg)
  • Develop and evaluate the efficacy of a recombinant NNV (Nervous necrosis virus) vaccine. (Vakharia)
  • Produce a bioamended activated carbon pellet seeded with PCB- degrading microorganisms to reduce the concentration of polychlorinated biphenyls (PCBs) in sediments. (Sowers)
  • Developing a sensing system comprising of ultra-low cost textile-based nonrigid capacitive sensor arrays and inertial sensors that allow individuals with upper extremity paralysis to control their appliances and security systems remotely. (Banerjee)
     
UNIVERSITY OF MARYLAND COLLEGE PARK
  • Staggered electrode multi-battery for emerging on-board power applications (Rubloff)
  • Developing MCube: A building energy monitoring, modeling and management software system (Srebric)
  • Creating real-time 3D prinitng, quality assurance and product acceptance testing (Schultheis)
  • Developing an add-on Brillouin biomechanics module for confocal microscopes (Scarcelli)
  • Developing VOLT: a tailored occupation specific language training in immersive virtual reality environments (Bunting)
  • Developing a mucosal vaccination against RSV infection (Li)
  • Developing a recurrent processing unit (RPU) for high performance computing (Lathrop)
  • Building-scale weather and energy forecast service (BuildECast) for electricity savings (Jin)
  • Developing novel polyphosphazene technology for stabilizing protein therapeutics (Andrianov)
  • Developing targeted enzymes for effective treatment of lysosomal disorders (Muro)
  • Developing drought-tolerant crop cultivars with improved water-use efficiency (Xiao)
  • Develop QUANTITY: A novel analysis kit for protein drug development (In collaboration with Johns Hopkins University). (Li)
  • Developing an integrated power electronic charger/converter for plug-in electric vehicles. (Khaligh)
  • Developing an efficient mucosal vaccination mediated by the Neonatal Fc Receptor. (Zhu)
  • Creating hemostatic bandages based on a new biocompatible polymer (In collaboration with University of Maryland Baltimore). (Raghavan)
  • Developing and testing protocols for scour sensing post deployment. (Tauros-Ph.2)
  • Developing novel acyclic cucurbituril molecular containers as broad spectrum reversal agents for neuromuscular block agents used during surgery. (Isaacs)
  • Developing a clinical assay that would provide a tool to improve time to diagnose and monitor disease progression in ALS and possibly other neuromuscular diseases (In collaboration with University of Maryland, Baltimore). (Chin)
  • Developing a vaccine against a significant swine pathogen, procine reproductive and respiratory syndrome virus (PRRSV). (Zhang)
  • Developing 2D hyperspectral imaging techniques for manufacturing yield and device failure analysis for photovoltaic cells and LEDs. (Bartolo)
  • Develop a new technology for the production of liposomal nanoparticle drugs in a unique continuous-flow manufacturing process. (DeVoe)
  • Develop data analysis tools on a user-friendly web interface and customize them for a variety of clients ranging from national chain restaurants to other establishments and local health departments in searching the existing nationwide food safety inspections database. (Bederson)
  • Developing a novel, generalized approach to the formulation of vaccines against Gram-negative pathogens (In collaboration with University of Maryland, Baltimore). (DeShong)
  • Customize Behavioral Activation Treatment for Depression (BATD) for a mobile platform to be used by clinicians and their patients by creating a BATD mobile application to be used in conjunction with therapy. (Lejeuz)
  • Developing a non-invasive way to evaluate the quality of a donor kidney known as kidney viability assessment system (KVAS). (Chen)

 

Back to Top